Complement Activation Signatures and Treatment in Systemic Lupus Erythematosus

Overview

Información sobre este estudio

The purpose of this study to look at certain blood proteins known as complement proteins in the whole blood of patients with systemic lupus erythematosus (SLE or lupus). We propose that the levels of these proteins will A) predict lupus disease activity, B) provide information regarding efficacy of treatment, and c) provide SLE diagnostic information.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

Subjects who are recruited to the study will donate blood.  We will try to obtain this sample during a previously scheduled blood draw to minimize the number of needle sticks.  However, we may draw blood solely for research purposes when necessary.   Details of sample collection for newly recruited subjects are described below:

  • Subjects will be enrolled in either an outpatient or inpatient setting:

Outpatients:

  1. Subjects may be enrolled in Rheumatology by trained interviewers (study staff), and blood may be drawn at the next visit for which they are scheduled to have blood drawn.The interviewer will explain what participation entails.
  2. Participants will be asked to sign a written consent form that will allow us to conduct research to identify markers that predict health and disease status and disease progression.
  3. Results of “c” will be obtained from the patient’s chart. Participants will donate blood (finger sticks or venipuncture) as clinically warranted for a period of 1 year. Some participants may have 1 visit and some may have 4 visits but these will be determined by the treating physician. All subjects will initially donate 4 mL of blood at the same time of obtaining consent (if the patient has not yet had a blood sample collected), or at the next scheduled phlebotomy appointment for blood collections. Participants may be asked to donate more blood in the future, if it is deemed clinically necessary. At the re-draws, a total of 4 mL blood will be drawn.See details below.
    1. Participants will be asked questions about their medical history, medication history, and demographics, and
    2. Physical examination

Inpatients:

 

 

 

  1. Patients will be enrolled during their inpatient stay and will have samples drawn during a scheduled blood draw whenever possible. 

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Timothy Niewold, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20308929

Mayo Clinic Footer